Biogen (BIIB) Says New Data at Cure SMA 2021 Highlight Long-Term Efficacy of SPINRAZA and its Commitment to Innovation in SMA Therapy
Go back to Biogen (BIIB) Says New Data at Cure SMA 2021 Highlight Long-Term Efficacy of SPINRAZA and its Commitment to Innovation in SMA Therapy| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 202.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $202.46 | 52 Week High | $333.65 | |||
| Open | $202.46 | 52 Week Low | $223.02 | |||
| Day High | $202.46 | P/E | 25.92 | |||
| Day Low | $202.46 | EPS | $7.81 | |||
| Volume | 16 | |||||
| (NASDAQ: IONS) | Delayed: 41.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.84 | 52 Week High | $62.68 | |||
| Open | $41.84 | 52 Week Low | $19.59 | |||
| Day High | $41.84 | P/E | N/A | |||
| Day Low | $41.84 | EPS | $0.00 | |||
| Volume | 208 | |||||
